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a b s t r a c t
Respiratory syncytial virus (RSV) is the major leading cause of infantile viral bronchiolitis. However,
cellular phenotypes contributing to the RSV protection and vaccine-enhanced disease remain largely
unknown. Upon RSV challenge, we analyzed phenotypes and cellularity in the lung of mice that were
naïve, immunized with formalin inactivated RSV (FI-RSV), or re-infected with RSV. In comparison with
naïve and live RSV re-infected mice, the high levels of eosinophils, neutrophils, plasmacytoid and
CD11bþ dendritic cells, and IL-4þ CD4þ T cells were found to be contributing to pulmonary
inﬂammation in FI-RSV immune mice despite lung viral clearance. Alveolar macrophages appeared to
play differential roles in protection and inﬂammation upon RSV infection of different RSV immune mice.
These results suggest that multiple innate and adaptive immune components differentially contribute to
RSV disease and inﬂammation.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Respiratory syncytial virus (RSV) is the major leading cause of
bronchiolitis in infants and in older populations (Stott and Taylor,
1985). In the 1960s, vaccination of young children was conducted
using formalin inactivated RSV (FI-RSV) vaccines with alum
adjuvant. Most vaccinated children were hospitalized due to
severe pulmonary disease during next epidemic season and
2 children died (Kapikian et al., 1969; Kim et al., 1969a). Histolo-
gical analysis revealed dramatically increased eosinophilic inﬁltra-
tion in the lungs (Kim et al., 1969a). Others demonstrated that
vaccine-enhanced disease was resulted from the induction of T
helper type 2 (Th2) cytokines, including interleukin-4 (IL-4), IL-5
and IL-13 (Johnson and Graham, 1999; Johnson et al., 2003).
However, it is still challenging to develop an effective and safe
vaccine which does not cause RSV disease despite several decades
of studies (Rudraraju et al., 2013).
Dendritic cells (DCs) as sentinel cells in the lung constantly
monitor for incoming foreign pathogens or antigens, playing a
pivotal role in the induction of RSV speciﬁc immune responses.
Different subsets of DCs inﬂuence the magnitude and quality of
the host response to RSV infection as well as RSV pathogenesis.
Murine DCs can be divided into conventional DCs and plasmacy-
toid DCs (pDCs) (Lambrecht and Hammad, 2012). The conventional
DCs (cDCs) in the lung are further divided into CD11bþ DCs and
CD103þ DCs. CD11bþ DCs are mainly involved in recruiting
leukocytes by producing proinﬂammatory cytokines and in prim-
ing effector CD4þ T cells. Whereas CD103þ DCs are known to be
effective in sampling foreign antigens in the airway lumen and in
priming naïve CD8þ and CD4þ T cells (Lukens et al., 2009). Lung
pDCs are an important producer of type I interferons, granting
them to activate antiviral functions of other cell types including
myeloid DCs, B cells, T cells, and natural killer cells (Colonna et al.,
2004; Fitzgerald-Bocarsly and Feng, 2007; Takagi et al., 2011). A
high level of inﬁltrating eosinophils is known to be associated with
inﬂammatory RSV vaccine-enhanced disease although direct roles
of eosinophilia in the RSV pathogenesis still remain controversial
(Castilow et al., 2008; Kim et al., 1969b).
Alveolar macrophages (AMs) are the ﬁrst line of innate immune
cells responding to incoming pathogens in the airways and play a key
role in regulating inﬂammatory responses (Sibille and Reynolds, 1990).
In response to RSV infection, AMs in humans are responsible for
producing numerous proinﬂammtory cytokines including TNF-α, IL-6,
IL-8, and IL-10 (Becker et al., 1991; Panuska et al., 1995). A recent study
has shown that AMs can regulate recruitment of inﬂammatory
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monocytes and monocyte-derived DCs via type I interferon dependent
manner upon RSV infection, which play an important role in RSV
disease severity (Goritzka et al., 2015). AMs as antigen presenting cells
in the lungs were also known to modulate DC migration and antigen
presentation (Holt, 2000; Jakubzick et al., 2006). In addition, AMs are
required for protection against several pathogens such as inﬂuenza
virus (Tumpey et al., 2005) and Klebsiella Pneumonia (Broug-Holub
et al., 1997). In contrast, improved protection against Mycobacterium
tuberculosiswas observed in the absence of AMs (Leemans et al., 2001).
The roles of AMs as a major airway cell type in the RSV
protection and disease as well as in the modulation innate and
adaptive immune cells largely remain unknown. One of major
goals in this study is to better understand potential roles of
multiple innate and adaptive cellular components in the RSV
protection and disease. Here we investigated cellular phenotypes
in the lung microenvironment of mice that were naïve, previously
immunized with FI-RSV, or re-infected with live RSV upon RSV
challenge. To understand the roles of AMs in protection and
inﬂammation upon RSV infection, the in vivo effects of AM-
depleting clodronate liposome (CL) treatment prior to RSV chal-
lenge were analyzed.
Results
RSV infection causes differential effects on alveolar macrophages in
RSV pre-immune mice
To investigate cellular phenotypes and cellularity in the protection
and pathogenesis of vaccine-enhanced RSV disease (ERD), mice
(n¼10) were i.m. immunized with FI-RSV or i.n. inoculated with
RSV (1106 PFU). Both FI-RSV immunization and live RSV infection
induced similar levels of serum IgG antibodies speciﬁc for RSV (Fig.
S1A). Live RSV reinfection but not FI-RSV immunization also raised
IgA antibodies in bronchoalveolar lavage ﬂuids (BALF) (Fig. S1B). RSV
speciﬁc antibody responses suggest that FI-RSV immunization and
RSV infections were properly performed as expected.
Clodronate liposome (CL) preferentially depletes alveolar macro-
phages (AMs) without affecting other cell types in the lung as fast as
within 4 h post-treatment (Thepen et al., 1989; van Rooijen et al.,
1997). Mock control mice (no immunization, no infection) were
sacriﬁced to determine the efﬁcacy of depleting AMs in BAL 5 days
after CL administration (100 μl of 30% CL) (Fig. 1A). The surface
markers (CD11cþCD11bF4/80þ) were used to analyze a population
of AMs by ﬂow cytometry (Hall et al., 2008). Consistent with a
previous study (Pribul et al., 2008), the percentage of F4/80þ AMs
was reduced to 8% in CL-treated naïve mice compared to 53% in the
untreated mice (Fig. 1A). As a result of CL treatment, the cellularity of
AMs was depleted up to 97% in naïve (Fig. 1B), FI-RSV and live RSV
immune mice prior to RSV challenge (data not shown), suggesting
that AM populations in naïve and RSV immune mice could be
depleted by CL administration.
Interestingly, RSV-infected naïve mice showed a lower level of
AM cellularity (12104/mouse) compared to uninfected naive
mice (17104/mouse) (Fig. 1B). FI-RSV and live RSV immune
mice showed a signiﬁcantly lower level (4.5104/mouse and
3.2104/mouse, respectively) of AMs in BAL upon RSV chal-
lenge compared to those in infected naïve mice (12104/mouse,
Naïve, Fig. 1B). CL treatment 4 h prior to RSV infection of naïve
mice resulted in approximately 50% reduction in AM cellularity
(5.6104/mouse Fig. 1B). Paradoxically, FI-RSV and live RSV
immune mice showed moderate increases in AM cellularity
(7.5104/mouse and 5.7104/mouse, respectively) rather
than depletion as a result of CL treatment (Fig. 1B). It is an
unexpected ﬁnding that the FI-RSV and live RSV groups with CL
treatment showed a trend of increasing the AM population after
RSV challenge. Taken together, when RSV challenge was followed,
the AM populations in the airways of FI-RSV immune and live RSV
reinfection mice were signiﬁcantly lower than those in naïve mice
with RSV infection.
Neutrophils are highly inﬁltrated into the airways of FI-RSV immune
mice
In contrast to low cellularity of CD45þ cells in uninfected naïve
mice, CD45þ leukocytes were signiﬁcantly increased to the high-
est levels in the airways of FI-RSV immune mice, followed by live
RSV reinfection mice day 5 after RSV challenge, and AM-depleted
naïve uninfected mice lowered CD45þ cells but not in other
groups (Fig. 2A). Monocytes (CD11bþLy6chiF4/80þ) and neutro-
phils (CD11bþLy6cþF4/80) were determined based on their
surface markers as described (Daley et al., 2008). The percentage
and number of monocytes were found to be highest in the airways
of naïve mice after RSV infection and substantial levels in the FI-
RSV group (Fig. 2B and C). It is noticeable that monocytes were
lowest in the live RSV group and increased after AM depletion
(Fig. 2B and C). In contrast, naïve mice showed the highest levels of
monocytes after RSV infection but the scale (103) is approxi-
mately 10–100 fold lower than that (105) of CD45þ leukocytes
(Fig. 2C). Most signiﬁcantly, percentage and cellularity of neutro-
phils was found to be highest in the FI-RSV group, low in other
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Fig. 1. Depletion of alveolar macrophages by clodronate liposomes, bronchoalveo-
lar lavage ﬂuids (BALF) were performed to collect immune cells by passing PBS
through the trachea after sacriﬁcing the mice day 5 post-challenge (n¼5).
(A) CD11c, CD11b, and F4/80 antibodies for ﬂow cytometry were used to analyze
the depletion of alveolar macrophages (AMs). (B) Total numbers of AMs in BAL
ﬂuids were analyzed in each group of mice. CL (n¼5): intranasal treatment with
30% of CL (100 μl) 4 h prior to RSV infection. The data are representative out of two
independent experiments with reproducible results. PBS: PBS control groups
(instead of CL). Statistical signiﬁcance was determined using one-way ANOVA or
an unpaired two-tailed Student's t test. Error bars are means7SEM of concentra-
tion or ratios from individual animals. *, Po0.05; **, Po0.01.
Y.-T. Lee et al. / Virology 485 (2015) 36–46 37
naïve or live RSV groups (Fig. 2C). Thus, these results suggest that
high levels of neutrophils recruited into the airways of FI-RSV
immune mice might have contributed to inﬂammatory lung
disease (Fig. 2B and D).
CD11bþ and plasmacytoid dendritic cells are signiﬁcantly recruited
into the lungs of mice with FI-RSV immunization and RSV infection
The markers such as CD11c, CD11b, CD103, B220, and MHCII for
ﬂow cytometry were used to separate different dendritic cells (DCs)
such as CD11cþCD11bþ DCs, CD11cþCD103þ DCs, and CD11cþ
B220þ DCs (Beaty et al., 2007; Sung et al., 2006). In contrast to high
cellularity of AMs, uninfected naïve mice did not show DCs in lungs
(Fig. 3). After RSV infection, different types of dendritic cells (DCs)
were differentially and signiﬁcantly recruited into the airways and
lungs of naïve unimmunized mice or immune mice with FI-RSV
immunization or RSV reinfections (Fig. 3). Plasmacytoid DCs (pDCs,
B220þCD11cþF4/80CD45þ) were observed at higher levels in the
airways and lungs of FI-RSV immune mice than those in the naïve and
live RSV groups day 5 post-RSV challenge (Fig. 3A and D, respectively).
As a result of AM depletion, an increase in lung pDCs was observed in
naïve mice with RSV infection but there was no statistical signiﬁcance
(Fig. 3D). CD103þ DCs (CD103þCD11cþF4/80CD45þ) were
observed in the airways of the live RSV group relatively at high levels
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Fig. 2. FI-RSV immune mice recruit CD45þ leukocytes and neutrophils into the airways upon RSV infection. The cells from the airways (BALF) of individual mice (n¼5 per
group) were collected 5 days after RSV challenges. Distinct cell subsets were analyzed using speciﬁc markers such as CD45, CD11c, CD11b, F4/80 and Ly6c. Total numbers of
(A) CD45þ leukocytes were analyzed in BAL ﬂuids, (B) the percentages of monocytes (CD11bþLy6chiF4/80þ) and neutrophils (CD11bþLy6cþF4/80) were shown on ﬂow
cytometry plots. The absolute numbers of (C) monocytes and (D) neutrophils were analyzed in BAL ﬂuids. The data were reproducible with two independent experiments.
Statistical signiﬁcance was determined using one-way ANOVA or an unpaired two-tailed Student's t test. Error bars are means7SEM of concentration or ratios from
individual animals. *, Po0.05; **, Po0.01; ***, Po0.001.
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(Fig. 3B). There was a moderate increase of CD103þ DCs in the
airways of the naïve and FI-RSV groups with CL treatment upon RSV
infection (Fig. 3B). CD11bþ DCs (CD11bþCD11cþF4/80CD45þ) were
observed at highest levels in the airways and lungs of the FI-RSV
group, and at substantial levels in naïve mice upon RSV infection
compared to those in the live RSV reinfection group (Fig. 3C and F).
Analysis of DCs in the airways and lungs suggests that high cellular
inﬁltrations of B220þ pDCs and CD11bþ DCs are likely contributing to
FI-RSV vaccination-associated pulmonary disease.
FI-RSV immune mice show signiﬁcant body weight loss upon RSV
infection
To elucidate the possible effects of AM depletion on body weight
changes of FI-RSV immunized or live RSV re-infected mice after RSV
challenge (2106 PFU), body weights of mice were monitored (Fig. 4).
The unimmunized naive group challenged with RSV displayed approxi-
mately 2.5% weight loss in PBS-treated mice and AM-depleted naïve
mice showed a better recovery in body weight than PBS-treated mice
day 5 post-RSV infection (Fig. 4A). The FI-RSV group revealed promi-
nent weight loss (approximately 9%) until day 2 post-challenge
compared to the naive or live RSV groups (Fig. 4B). The CL-treated FI-
RSV group displayed a pattern of progressive weight recovery from day
2 post-challenge. In contrast, PBS-treated FI-RSV immunized mice
revealed a second wave of body weight loss day 5 post-challenge
(Fig. 4B). The live RSV group showed an early loss in body weight loss
and a progressive recovery although PBS-treated live RSV mice showed
more weight loss (approximately 7%) day 1 post-RSV re-infection
(Fig. 4C). These results suggest that FI-RSV immunization and live
RSV infection cause signiﬁcant illness of weight loss respectively upon
RSV challenge. An increase in AMs and CD103þ DC populations as a
result of CL treatment prior to RSV infection might have protective
effects on preventing severe weight loss in the FI-RSV immune mice.
To determine whether AM depletion inﬂuenced lung viral
clearance, lung RSV titers were determined day 5 post-challenge.
High RSV titers were observed in the lungs of the unimmunized
naive group whereas the FI-RSV and live RSV groups cleared RSV
titers to a detection limit, and no difference was observed in viral
clearance with or without CL treatment (Fig. 4D). Also, there was
no difference in IgA antibody responses between PBS- and CL-
treated live RSV mice (Fig. S2).
FI-RSV immunized mice show G peptide-speciﬁc CD4þ T cells
producing IL-4 cytokine
It has been shown that antigen-speciﬁc T cells play dual roles in
both protection and immunopathology during RSV infection
(Olson and Varga, 2008). To investigate whether AM population
would modulate IFN-γ-producing T cell responses, lung T cells
from unimmunized naïve and immunized mice day 5 post-
challenge were stimulated with the synthetic F85–93 (KYKNAVTEL)
(Chang et al., 2001) and G183–195 (WAICKRIPNKKPG) (Varga et al.,
2000) peptides speciﬁc for CD8 and CD4, respectively. High
numbers of IFN-γ positive spots with stimulation of F peptides
were similarly detected in the FI-RSV and live RSV groups (Fig. 5A).
CL-treatment resulted in reduced numbers of IFN-γ-producing cell
spots speciﬁc for F peptides in FI-RSV immunized mice, which
might be associated with a better recovery in weight loss (Fig. 5A).
In addition, total numbers of IL-4þ spots with stimulation of G
peptides in FI-RSV immunized mice were observed at signiﬁcantly
higher levels than those in unimmunized naïve and live RSV
infected mice (Fig. 5B). These results suggest that high levels of
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RSV G speciﬁc IL-4 producing CD4þ T cells contribute to vaccine-
enhanced disease in FI-RSV immune mice upon RSV infection.
DC migration into the draining lymph nodes is correlated with lung
viral loads
To further investigate whether respiratory DC migration to
draining lymph nodes (dLNs) would be correlated with viral loads
and inﬂuenced by AM population, the numbers of migratory lung
DCs were analyzed in the mediastinal lymph node (MLN) of
immunized mice 5 days after RSV challenge. There were no
signiﬁcant differences in PBS- and CL-treated mice despite a trend
of increasing DC migration into MLN in CL-treated FI-RSV immu-
nized mice (Fig. 6). Cellularity of CD103þ DCs, CD11bþ DCs, and
B220þ pDCs in the MLNs was observed at signiﬁcantly higher
levels in naïve mice after RSV infection than those in the FI-RSV
and live RSV groups, which is different from a pattern of various
DC populations in the airways and lungs (Fig. 3). These results
suggest a signiﬁcant correlation between lung viral loads and
various subsets of DC migration into MLN.
FI-RSV immune mice show extensive eosinophil inﬁltration in lungs
upon RSV infection
We analyzed the possible effects of AMs on eosinophil inﬁltration
into the airways using eosinophil markers (CD11bþCD11cSiglecFþ)
(Stevens et al., 2007). Interestingly, depletion of AMs in the airways of
naïve mice resulted in approximately a four-fold increase in eosino-
phils 5 days after RSV infection (Fig. 7A and B). The live RSV group
with CL treatment showed a moderate increase in the cellularity of
eosinophils in the airways (Fig. 7B). Eosinophils were observed at the
highest level in the FI-RSV group compared to those of unimmunized
and live RSV immunized groups (Fig. 7B and C, respectively).
Furthermore, a ratio of eosinophils relative to AMs in the airways of
FI-RSV immunized group was higher (approximately 1.8 fold) than
those in unimmunized and live RSV immunized groups (Fig. 7D).
These results suggest that an unbalance in inducing high levels of
eosinophils and decreasing AMs plays a role in causing severe
pulmonary inﬂammation upon RSV infection.
FI-RSV immunization causes severe pulmonary inﬂammation and
mucus production upon RSV infection
To further understand the possible effects of CL treatment on
pulmonary histopathology, histological analysis was performed in
the lung tissue sections day 5 post-challenge. In the analysis of H
and E staining, leukocyte inﬁltrates and histopathological inﬂam-
mation were observed at the highest levels in the lung tissues
from FI-RSV immune mice (Fig. 8A). Histopathological scores
showed an increasing trend around the airways, blood vessels
and interstitial area of FI-RSV immune mice but there was no
signiﬁcant difference as a result of CL treatment prior to RSV
infection (Fig. 8B, C and D, respectively). In particular, highest
levels of PAS positivity and eosinophils were detected in FI-RSV
immune mice and CL treatment resulted in a further increase in
PAS positivity, indicating more mucus production (Fig. 8E and F,
respectively). Importantly, as a result of AM depletion, naïve mice
showed a pattern of increasing inﬂammation in the airways, blood
vessels and PAS positivity after RSV challenge (Fig. 8B, C and E).
These data implicate that FI-RSV immunization causes severe
pulmonary inﬂammation and mucus production and that AM
population plays a differential role in modulating pulmonary
inﬂammation in nave and immune mice upon RSV infection.
Discussion
A better understanding of vaccine-enhanced RSV disease is expected
to provide insights into developing a safe vaccine against RSV. However,
cellular phenotypes and cellularity in the protection and pulmonary RSV
disease after vaccination are poorly understood. In this study, we have
focused on comparative analysis of cellular phenotypes in the airways
(BAL) and lungs of mice that were under different immune status (naïve,
naïveþRSV, FI-RSVþRSV, live RSV reinfectionsþRSV). We found highly
dynamics in cellular phenotypes and cellularity, which were differentially
modulated depending on the pre-existing immune status of mice with
immunization and infections. AMs were found to be high in naïve mice,
but low in naïve mice after RSV infection, and further reduced in FI-RSV
or live RSV mice. The airways of FI-RSV immune mice were found to
contain the highest levels of CD45þ leukocyte cellularity, neutrophils,
and eosinophils as well as plasmacytoid and CD11bþ conventional DCs.
Our results suggest that multiple granulocytes and DCs as well as RSV
speciﬁc CD4þ T cells inﬁltrated into the lung of FI-RSV immune mice at
high levels might have contributed to vaccine-enhanced pulmonary
inﬂammation.
RSV infection resulted in differential effects on lowering AM
populations in the airways of mice depending on the pre-existing
immune status. Infection of naïve mice with RSV led to a moderate
decrease in AMs in the airways. Interestingly, upon RSV infection, the
cellularity of AMs in the airways of mice with previous FI-RSV
immunization or live RSV reinfectionwas found to be further reduced
to approximately 30% of those in naïve mice with RSV infection. It is
unclear how pre-existing RSV immunity leads to signiﬁcant decreases
in AMs in the airways of immune mice compared to those in naïve
mice upon RSV challenge infection. Decreases in AM populations
were due to RSV infection and not because of immunization since
AMs were not affected by immunization and maintained in immune
mice at a level similar to that of naïve mice before RSV infection (data
not shown). One possibility is that AMs sensing virus and virus-
immune complexes are preferentially depleted or moving away from
the airways. CL is a well-known chemical in depleting macrophage
phenotypic cells at a fast kinetics (Van Rooijen and Sanders, 1994). As
a result of CL treatment, AM populations were efﬁciently depleted in
the airways from naïve mice (Fig. 1B). Before RSV challenge, FI-RSV
and live RSV immune mice showed high levels of AMs in bronch-
oalveolar lavage (BAL) ﬂuids, which were found to be sensitive to CL
treatment in an independent set of mouse experiments. After RSV
challenge, FI-RSV and live RSV immune mice showed signiﬁcantly
lower levels of AMs in BAL ﬂuids even in the absence of CL treatment
compared to those of naïve mice with RSV infection. We expected
that CL treatment would effectively deplete AM populations in naïve
mice regardless of RSV infection. However, it may be possible that
intrinsic properties of AMs might have changed to be less sensitive to
CL as a result of RSV infection. Alternatively, CL treatment and RSV
infection might have induced pulmonary inﬂammation which
resulted in inﬂux of new AM population until day 5.
In naïve mice after RSV infection, AM depletion resulted in an
increase in different dendritic cells (lung pDCs, CD103þ DCs), and
eosinophils, all or some of which together or independently might
have contributed to a better recovery without a second wave of
weight loss. Different strains of RSV were also known to inﬂuence
a differential weight loss pattern (Stokes et al., 2011). Depletion of
AMs in naïve mice also resulted in decrease in Th2 cytokines and
an increase in chemokine MIP-1β which is chemoattractant for
natural killer cells, monocytes, and eosinophils (data not shown).
Meanwhile, there was no difference in lung viral clearance in naïve
mice with and without AM populations. A previous study reported
that early proinﬂammatory IL-6 and TNF-α cytokines were mark-
edly reduced in naïve mice with AM depletion during RSV
infection (Pribul et al., 2008). Similar to RSV infection, a number
of proinﬂammatory cytokines were shown to be dramatically
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reduced by depleting AMs prior to inﬂuenza virus infection
(Tumpey et al., 2005).
As a result of CL treatment, we observed an unexpected out-
come of a moderate increase rather than decrease in AM popula-
tions in the airways from FI-RSV immune mice after RSV challenge
infection. It is not clear yet how RSV infection causes differential
effects on the airway AMs in RSV pre-immune mice. In line with
this change in AM cellularity in the FI-RSV group, we also found an
increase in monocytes, in CD103þ DCs in the airways, and in
various respiratory DC migrations (CD103þ , CD11bþ , B220þ) into
the draining lymph nodes, and a moderate decrease in airway
plasmacytoid DCs. These multicellular changes with CL treatment
of the FI-RSV group together with reduced T helper type 2 (Th2)
cytokines (data not shown) and lower RSV speciﬁc T cell responses
might have resulted in a better recovery without experiencing the
second wave of weight loss. In line with a ﬁnding (Stokes et al.,
2011), RSV infection resulted in the differential weight loss in mice
vaccinated with FI-RSV after RSV challenge. The early release of
cytokines and innate immune cell inﬁltrates may contribute to the
ﬁrst wave of loss in body weight, but IL-4 or IFN-γ producing T
cells may have impacts on the second wave. However, CL treat-
ment of FI-RSV immune mice resulted in a trend of increasing
multiple cells including leukocytes, monocytes, and CD103þ DCs,
all of which might have contributed to a moderate increase in
histopathology including PAS positive mucus production. Similar
or different effects were observed in the live RSV group although
these changes were minimal. After CL treatment of the live RSV
group, there was a pattern of increasing monocytes and eosino-
phils in the airways, but cytokine ELISA with BAL ﬂuids revealed a
moderate decrease in Th2 cytokines (data not shown). Naïve mice
with AM depletion showed a proﬁle of increasing chemokines,
eosinophils, pDCs and CD103þ DCs in lungs as well as better
recovery in body weight and less inﬂammation around blood
vessels. A balanced and low level of inﬂammation would have
beneﬁcial effects in naïve mice upon infection. In support of this,
activated mouse eosinophils were recently shown to protect
against lethal respiratory virus (Percopo et al., 2014). The protec-
tion and disease outcomes observed in the naïve, FI-RSV, and live
RSV groups might need to be differentially interpreted depending
on the pre-existing immune conditions. Therefore, it is important
to carefully consider changes in multiple cellular phenotypes as
well as protection and pathology together.
This study reveals dynamic changes in granulocyte types and
cellularity in the airways of the naïve, FI-RSV, and live RSV groups
upon RSV challenge compared to naïve mice (no immunization, no
infection). (1) AM populations were signiﬁcantly reduced in the
airways of naïve mice with RSV infection, and further reduced in
the FI-RSV and live RSV groups. (2) CD45þ leukocyte populations
were highest in the FI-RSV group and then followed by live RSV
mice with reinfections. (3) Monocytes were recruited at the
highest level in the naïve group upon RSV infection and followed
by the FI-RSV group. (4) Most prominently, neutrophils and
eosinophils as well as IL-4 cytokine secreting T cells were recruited
at the highest levels in the FI-RSV group. Our results suggest that
induction of Th2 cytokines and inﬁltration of neutrophils and
eosinophils appear to be an independent outcome because CL-
mediated reduction of Th2 cytokine production did not inﬂuence
the recruitment of these cells.
The possible roles of respiratory DCs in the RSV inﬂammatory disease
largely remain unknown although DCs play a central role in the induction
of the RSV-speciﬁc adaptive immune response. Depletion of pDCs prior to
RSV infection was shown to increase pulmonary inﬂammation and
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mucus production (Smit et al., 2006; Wang et al., 2006). Also, lung T cells
from pDC-depleted mice were demonstrated to secrete more Th2
proinﬂammatory cytokines (IL-4, IL-5, IL-13) as well as Th1 proinﬂam-
matory cytokine IFN-γ upon in vitro stimulation (Smit et al., 2006).
However, our results of differential recruitment of various DCs in the
airways and the MLN suggest alternative roles of DCs in the RSV
protection and disease. The FI-RSV group recruited pDCs and CD11bþ
DCs into the airways and lungs at the highest level whereas the live RSV
groups showed a low level of both DC populations. Meanwhile CD103þ
DCs were observed at high levels in the airways of live RSV mice. Naïve
mice with RSV infection showed a similar level of pDCs and moderately
higher levels of CD11bþ DC compared to the live RSV group. In contrast
to pDCs and CD11bþ DCs, relatively low levels of CD103þ DCs were
observed in the airways of FI-RSV mice compared to live RSVmice. Since
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the FI-RSV group showed signiﬁcantly more pulmonary histopathology,
high levels of pDCs and CD11bþ DCs together with eosinophils and
neutrophils in the lungs might have a role in the progress of FI-RSV
vaccine-induced pulmonary inﬂammation. In contrast, the naïve RSV
group showed the highest levels of monocytes into lungs as well as
different phenotypic respiratory DCs (CD103þ , CD11bþ , B220þ) migrat-
ing into the MLN, exhibiting a correlation with lung viral loads. The FI-
RSV group showed high levels of IL-4þ T cell responses stimulated with
RSV G peptide compared to those in the live RSV group, which may be
associated with an accelerated pulmonary immunopathology as consis-
tent with a previous study using a recombinant RSV vaccine (Bukreyev
et al., 2005). A comparative analysis implicates that high cellularity of
inﬁltrates (neutrophils, eosinophils, plasmacytoid and CD11bþ DCs, G-
speciﬁc T cell responses) seems to be major contributors to FI-RSV
vaccination enhanced pulmonary inﬂammation.
In conclusion, this study demonstrates multiple immune para-
meters that might be involved in the RSV protection and pulmon-
ary inﬂammatory disease progression. Lung viral clearance, body
weight loss, innate immune cell inﬁltration, Th1 and Th2 cell
responses, and pulmonary inﬂammation may be interdisciplinary
protection and independent disease parameters in mice. Lung viral
clearance seems to be mainly dependent on pre-existing RSV
speciﬁc (humoral) immune responses. Pulmonary inﬂammation
can be observed in mice even with lung viral clearance. AMs,
monocytes, neutrophils, eosinophils, and different phenotypic DCs
are highly dynamic in the lung microenvironment depending on
the status of mice with naïve, ﬁrst RSV infection, repeated RSV
infections, or FI-RSV immunization and RSV infection. High levels
of eosinophils and neutrophils as well as certain respiratory DCs
(pDCs, CD11bþ DCs) and Th2 cells are likely to be the major
contributing cellular parameters to pulmonary inﬂammation in FI-
RSV immune mice after RSV infection. The results from this study
provide important observations on possible protective immune
cellular correlates inducing protection but also preventing RSV
pulmonary disease. This study further provides new insight into
developing a safe and effective RSV vaccine which induces
protection against RSV by conferring immune correlates but with-
out causing pulmonary inﬂammatory disease. A comparison with
RSV vaccine candidates would further validate the ﬁndings of
cellular immune parameters contributing to safe RSV vaccination.
According to a previous ﬁnding, we found that mice vaccinated
with a cocktail vaccine of F DNA and virus-like particles containing
RSV fusion and attachment glycoprotein induced low bronchoal-
veolar cellularity, low levels of granulocytes, no sign of eosinophi-
lia upon RSV challenge, which were similar to those in live RSV-
reinfected mice (Ko et al., 2015). This implies that comparing
immune cellular correlates between FI-RSV and live RSV reinfec-
tion might provide useful parameters to predict protection against
RSV and to prevent RSV disease.
Materials and methods
Mice and FI-RSV
Female BALB/c mice aged 6–8 weeks were purchased from the
Harlan (Indianapolis, IN). In order to obtain a stock of respiratory
syncytial virus (type A2 strain), RSV was grown in HEp-2 cells
which were cultured in Dulbecco's modiﬁed eagle medium
(DMEM) containing 2% fetal bovine serum, penicillin and strepto-
mycin. RSV was then harvested after sonication of infected HEp-2
cells and inactivated with 10% formalin (1:400 vol/vol) as pre-
viously described (Quan et al., 2011). Formalin inactivated RSV (FI-
RSV) was puriﬁed by ultracentrifugation. Inactivated RSV was
adsorbed to aluminum hydroxide adjuvant (alum, 4 mg/ml) and
used for immunization.
Immunization and viral challenge
Female BALB/c mice were intranasally (i.n.) infected with live
RSV A2 strain (1106 PFU) or intramuscularly (i.m.) immunized
with FI-RSV (2 mg) at weeks 0 and 4 (n¼10). Immunized mice
were anesthetized by isoﬂurane (Baxter, Deerﬁeld, IL) and i.n.
challenged with RSV A2 strain (2106 PFU) in 50 μl of phosphate-
buffered saline (PBS) at 6 weeks after boost immunization. Half of
the mice in each group (n¼5) were i.n. given with 30% of
clodronate liposome (CL; Clodronate Liposomes, Netherlands) 4 h
prior to RSV infection and 5 days later, depletion of AMs was
analyzed by ﬂow cytometry. RSV challenged mice were daily
monitored to record body weight changes for 5 days. To compare
the efﬁcacy of vaccination, unimmunized naive mice were used as
a negative-control group. Experimental data were conﬁrmed by
two independent experiments. All animal studies were approved
and conducted under the guidelines by Georgia State University's
IACUC (A11026).
Serum preparation and humoral immune responses
The blood samples after prime and boost immunization were
collected from naïve mice and immune mice with FI-RSV or live RSV.
The speciﬁc serum antibody titers against FI-RSV as a coating antigen
were determined by enzyme-linked immunosorbent assay (ELISA) as
described (Lee et al., 2014; Quan et al., 2007). Brieﬂy, FI-RSV was used
to determine the amount of speciﬁc antibodies. FI-RSV (4 mg/ml) in
coating buffer was coated on 96-well microtiter plates (Nunc, Roche-
ster, NY) and incubated for overnight at 4 1C. The 96-well ELISA plates
were washed with PBS containing 0.05% Tween 20 (PBST) and 3% BSA
in PBST was used for blocking reagents for 90min at 37 1C. The blood
samples were serially diluted in PBS and incubated for 90min at 37 1C.
Secondary goat anti-mouse IgG (Sourthern Biotech, Birmingham, AL)
antibodies conjugated with horseradish peroxidase (HRP) were incu-
bated for 90min and then the tetramethybenzidine (TMB) peroxidase
substrate (Sigma-Aldrich, St. Louis, Mo) was used as the a substrate.
The optical density (OD) values were measured using an optical
spectrophotometer reader at 450 nm. The total antibody concentration
was determined with respect to quantitative standard antibody con-
centration by using puriﬁed mouse IgG and IgA antibodies.
Cell preparations and ﬂow cytometry
Bronchoalveolar lavage ﬂuids (BALF) were harvested using PBS
to collect non-adherent cells from the lung airways. After collect-
ing BALF, lung tissues were homogenated and cells were then
passed through strainer and spun on 44/67% Percoll gradients at
2800 rpm for 20 min. A lung cell band which contained most
immune cells was harvested. The frosted glass microscope slides
were used to make cell suspensions from the mediastinal lymph
nodes (MLN) and spleens. Red blood cells were lysed with
ammonium chloride and lymphocytes were ﬁltered through cell
strainers. Flow cytometric analysis were carried out using cell
surface marker antibodies speciﬁc for CD3, CD4, CD8, CD11b,
CD11c, CD45, F4/80, Siglec F and Ly6c (eBioscience or BD Pharmin-
gen). The Becton-Dickinson LSR-II/Fortessa ﬂow cytometer (BD,
San Diego, CA) was used to analyze distinct populations from the
tissues and acquired samples were further analyzed by using
Flowjo software (Tree Star Inc.).
Enzyme-linked immunospot (EISPOT) assay
Cytokine secreting cell spots were determined on Multi-screen
96 well plates. Brieﬂy, lymphocytes (5105 cells/well) from lung
tissues were cultured in the presence of the synthetic F85–93
(KYKNAVTEL) (Chang et al., 2001) and G183–195 (WAICKRIPNKKPG)
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(Varga et al., 2000) peptides speciﬁc for CD8 and CD4, respectively.
Interferon gamma (IFN-γ) producing cell spots were counted using
BioSys ELISpot reader.
RSV immuno-plaque assay
RSV lung viral titers were determined by an immune plaque
assay using anti-F monoclonal antibody (Millipore) as described
previously (Quan et al., 2011).
Lung histopathology
The lung tissues were harvested from RSV infected animals and
ﬁxed with 10% neutral buffered formalin for 48 h. Formalin ﬁxed
lung tissues were transferred into 70% ethanol and followed by the
routine histology staining processes of hematoxylin and eosin (H
and E), periodic acid-Schiff stain (PAS) or hematoxylin and congo
red (H and CR) as described (Meyerholz et al., 2009). To analyze
pneumonia in enhanced RSV disease model, the inﬂammation
scoring system was applied in the bronchi, blood vessels, and
interstitial space as described previously (Melendi et al., 2007).
Statistics
Unless otherwise stated, all results were presented as mean-
s7SEM (standard error of mean). One-ANOVA or an unpaired
two-tailed Student's t test was used for statistical signiﬁcance for
all experiments. We analyzed all data with statistical Prism soft-
ware (GraphPad software Inc, San Diego, CA). The comparisons
that were used to generate P values are indicated by horizontal
lines (*Po0.05, ** Po0.01, *** Po0.001).
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